Drug Profile
Pamufetinib - Taiho Pharmaceutical
Alternative Names: TAS-115Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Taiho Pharmaceutical
- Class Amides; Antifibrotics; Antineoplastics; Fluorobenzenes; Quinolines; Small molecules; Thiones
- Mechanism of Action Hepatocyte growth factor inhibitors; Proto-oncogene protein c-met inhibitors; Vascular endothelial growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Osteosarcoma
- Phase II Idiopathic pulmonary fibrosis; Interstitial lung diseases; Prostate cancer
- Phase I Solid tumours
Most Recent Events
- 30 Sep 2023 Phase-I clinical trials in Solid tumours (Combination therapy with zimberelimab) in Japan prior to September 2023 (PO) (Otsuka Pharmaceutical pipeline, November 2023)
- 30 Sep 2023 Phase-II clinical trials in Interstitial lung diseases in Japan prior to September 2023 (PO) (Otsuka Pharmaceutical pipeline, November 2023)
- 30 Dec 2021 Taiho Pharmaceutical suspends patient enrolment in a Phase-III clinical trial in Osteosarcoma (In adults, In children, In adolescents, Late-stage disease) in Japan (PO), prior to December 2021 (JapicCTI205335)